EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

Systemic lupus erythematosus (SLE) is a latent ... and successfully developed a novel disease risk prediction model for SLE that can be used as a new SLE disease risk prediction aid and contribute to ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN ... Obinutuzumab was well tolerated and no new safety ...

In a new study published in Lupus Science & Medicine, researchers assessed clinical trial perceptions among a predominantly Black cohort of participants with systemic lupus erythematosus (SLE).

Bacteria in the gut have been implicated in autoimmune diseases, like lupus, that don't primarily affect the gastrointestinal ...

Lupus, or systemic lupus erythematosus, often causes cutaneous lupus, leading to rashes, hair loss, and skin scarring. These rashes result from immune-driven inflammation. Standard treatment ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Lupus is a chronic autoimmune disease that disproportionately affects racial and ethnically minoritized populations, ...

People with lupus have a higher risk of hearing loss due to inflammation that can damage the inner ear and auditory pathways. Hearing loss is a lesser-known complication of lupus, but it can ...

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight ... Since the 2019 update, the pace of new developments in SLE has accelerated. A second biological drug, ...